Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
No open-market purchases or sales by Vir Biotechnology, Inc. insiders were filed in the last 90 days; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vir Biotechnology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vir Biotechnology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| More Robert J | Director | 517,917Indirect | Aug 12, 2026 | 2 |
| Coughlin Timothy | Director | 16,000 | Jun 10, 2026 | 1 |
| Napolitano Janet | Director | 21,216 | Jun 2, 2026 | 2 |
| Sabatini Brent | SVP, Chief Accounting Officer | 61,902 | Jun 2, 2026 | 5 |
| Bischofberger Norbert W | Director | 21,333 | May 28, 2026 | 1 |
| Hatfield Jeffrey S. | Director | 39,806 | May 28, 2026 | 1 |
| Sigal Charles Elliott | Director | 39,806 | May 28, 2026 | 1 |
| Farid Ramy | Director | 32,000 | May 28, 2026 | 1 |
| Sato Vicki L | Director | 1,078,391 | May 4, 2026 | 9 |
| De Backer Marianne | President and CEO | 286,650Indirect | Apr 30, 2026 | 4 |
| O'Byrne Jason | EVP & Chief Financial Officer | 2,500Indirect | Mar 23, 2026 | 4 |
| Eisner Mark | EVP and Chief Medical Officer | 154,024 | Feb 26, 2026 | 2 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec | 112,982 | Feb 26, 2026 | 4 |
| SB Investment Advisers (UK) Ltd | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| Softbank Vision Fund (Aiv M1) L.P. | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| SVF Endurance (Cayman) Ltd | 10% Owner | 13,728,924Indirect | Dec 3, 2025 | 11 |
| Ramasastry Saira | Director | 22,619 | Jun 2, 2025 | 0 |
| Scangos George A | Director | 698,239 | Feb 25, 2025 | 0 |
| Hanly Ann M. | EVP & Chief Technology Officer | 117,901 | Feb 25, 2025 | 0 |
| Nelsen Robert | Director | 584,148 | Jun 3, 2024 | 0 |
| Lee Sung | EVP & Chief Financial Officer | 100,492 | Mar 28, 2024 | 0 |
| Pang Phillip | EVP & Chief Medical Officer | 250,111 | Feb 26, 2024 | 0 |
| Rice Steven J. | Chief Administrative Officer | 106,840 | Jun 2, 2023 | 0 |
| Sharp Phillip A | Director | 121,174 | May 24, 2023 | 0 |
| Perez Robert J | Director | 15,806 | May 24, 2023 | 0 |
| Friedl-Naderer Johanna | EVP & Chief Operating Officer | 148,518 | Mar 7, 2023 | 0 |
| Horn Howard | CFO | 230,712 | Feb 24, 2023 | 0 |
| Crandell Keith | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| Bybee Clinton | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Fund IX, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Fund IX Overage, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX Overage, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX, L.P. | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| ARCH Venture Partners IX, LLC | 10% Owner | 61,160Indirect | Sep 7, 2022 | 0 |
| Virgin Herbert | EVP, Research & CSO | 262,500 | Aug 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 (view filing) | Apr 6 | 1 day | De Backer MariannePresident and CEO | SSale | −72.6K | $9.16 | −$664.6K | −7.1%948.1K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Sato Vicki LDirector | SSale | −22.0K | $10.05 | −$221.1K | −2.0%1.08M after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Sabatini BrentSVP, Chief Accounting Officer | SSale | −379 | $9.45 | −$3.58K | −0.6%61.9K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Napolitano JanetDirector | SSale | −3.20K | $9.45 | −$30.2K | −13.1%21.2K after | 10b5-1 |